Advanz Pharma, others see UK CMA thyroid drug-pricing fines upheld by appeal court
Fines imposed by the UK competition regulator on drugmaker Advanz Pharma and private equity groups Cinven and HgCapital over anticompetitive thyroid drug pricing were collectively upheld today by the UK Court of...To view the full article, register now.
Already a subscriber? Click here to view full article